Average Insider

Where insiders trade, we follow

$ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Healthcare
Sector
Biotechnology
Industry
Daniel J. O'Connell
CEO
61
Employees
$2.25
Current Price
$164.76M
Market Cap
52W Low$1.10
Current$2.2546.0% above low, 54.0% below high
52W High$3.60

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00--All Sells
Sells24$89,512.1438,700
2 monthsBuys00--All Sells
Sells24$89,512.1438,700
3 monthsBuys00--All Sells
Sells24$89,512.1438,700
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jun 16, 2026
Porter Derrell
Director
Sale12,800$2.33$29,772.80View Details
Jun 15, 2026
Porter Derrell
Director
Sale6,460$2.35$15,148.70View Details
Jun 17, 2026
Porter Derrell
Director
Sale13,040$2.33$30,318.00View Details
Jun 9, 2026
Fountain Nathan B
Director
Sale6,400$2.23$14,272.64View Details
44 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
May 11, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
4 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.5.2